As CRISPR–Cas adoption soars, summit calls for genome editing oversight
By Eric Smalley,
Nature Biotechnology
| 06. 06. 2018
Researchers are using a pair of initiatives, launched within a few days of each other, to widen the discussion about genome editing oversight to include countries often excluded from the conversation. At a meeting in Paris on March 23, a group of European biotech researchers launched the Association for Responsible Research and Innovation in Genome Editing (ARRIGE). Two days earlier, Nature published a call by two science, technology and society scholars to establish a global gene editing observatory (Nature 555, 435–437, 2018). The initiatives...
Related Articles
Artificial Intelligence (AI) has been a major focus of news recently, as it should have been, under the appropriately ridiculous name of Hugging Face, “a leading collaboration platform and community hub for machine learning, artificial intelligence, and data science.” In July, Hugging Face was hacked. The platform itself responded:
Earlier this week, we detected and responded to an intrusion into part of our production infrastructure. This one was different from anything we had handled before in one important way...
By Miryam Naddaf, Nature | 09.21.2026
A wave of epigenetic therapies is offering hope as ways to cure chronic hepatitis B — a lingering liver infection that is caused by the hepatitis B virus (HBV) and affects more than 250 million people around the world. Currently...
By Karen Weintraub, Endpoints News | 09.16.2026
To better understand certain neuropsychiatric disorders, researchers at Stanford University have bred rodents that lack a cortex and hippocampus and then replaced those missing brain cells with human ones.
The altered mice, a scientific first, provided insights that would not...
By Ryan Cross, Endpoints News | 09.02.2026
The deaths of two children who received CRISPR therapies in China have rattled scientists who work on similar genetic medicines in the US, adding new fuel to a yearslong debate about the danger of the gene therapy field’s most-used delivery...
